Press Release: European Medicines Agency confirms positive benefit-risk balance of Protelos/Osseor but recommends new contraindications and revised warnings

Author (Corporate)
Series Title
Series Details EMA/CHMP/185175/2012 (16.3.12)
Publication Date 16/03/2012
Content Type

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), in March 2012, finalised a review of Protelos and Osseor (strontium ranelate), from Les Laboratoires Servier. The Committee concluded that these medicines remain an important treatment for women with osteoporosis but that changes to the prescribing advice are necessary to better manage associated risks.
Source Link http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2012/03/news_detail_001471.jsp&mid=WC0b01ac058004d5c1&murl=menus/news_and_events/news_and_events.jsp
Related Links
EMA: Press Release: EMA/CHMP/185175/2012 (16.3.12): European Medicines Agency confirms positive benefit-risk balance of Protelos/Osseor, but recommends new contraindications and revised warnings http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2012/03/WC500124206.pdf
Subject Categories
Countries / Regions